Day: July 4, 2024

Escondida | BHP initiates environmental processing to implement a truck transportation system based on an electric trolley

Written by Customer Service on . Posted in Public Companies.

Electric trolley system at a mine site A trolley to electrically assist the movement of extraction trucks. The project will allow the mining company to advance BHP’s global target of net zero operating greenhouse gas emissions by 2050. It considers an investment of approximately US$ 250 million for the installation of infrastructure that will electrically assist the movement of extraction trucks, in areas where the highest fuel consumption currently takes place. SANTIAGO, Chile, July 03, 2024 (GLOBE NEWSWIRE) — Escondida | BHP submitted an Environmental Impact Statement (DIA) to the Environmental Impact Assessment System (SEIA), to advance in the “Implementation of the Mining Truck Electrification System in Escondida Norte” project, which seeks to assist the movement of these pieces of equipment inside...

Continue reading

Intermap Announces Private Placement Financing

Written by Customer Service on . Posted in Public Companies.

Proceeds to fund contracts with the Indonesian government, U.S. Air Force and other clients DENVER, July 03, 2024 (GLOBE NEWSWIRE) — Intermap Technologies (TSX: IMP; OTCQB: ITMSF) (“Intermap” or the “Company”), a global leader in 3D geospatial products and intelligence solutions, announces a new financing. The Company is offering up to a maximum of 4,300,000 Class “A” common shares of the Company (“Common Shares”), which upon issuance, will rank pari passu in all respects with the Company’s existing issued Common Shares, at a price of C$0.45 per Share for maximum gross proceeds of C$1,935,000.00 (the “Offering”). In connection with this Offering, Intermap has engaged a third-party finder (the “Finder”) to conduct a best-efforts private placement of the Common Shares. The Finder will receive a fee of: (i) an aggregate cash fee equal...

Continue reading

Psyence Biomedical Ltd. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Written by Customer Service on . Posted in Public Companies.

NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM) announced that it received a notification letter dated June 27, 2024, from the Listings Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the closing bid price per share of the Company’s common shares was below $1.00 for a period of 30 consecutive business days and that the Company did not meet the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), Nasdaq provided the Company with 180 calendar days, or until December 24, 2024 (the “Compliance Period”), to regain compliance with the Minimum Bid Price Rule. If at any time during the Compliance Period, the closing bid price...

Continue reading

HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status

Written by Customer Service on . Posted in Public Companies.

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 04, 2024 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the New Drug Application (“NDA”) for tazemetostat for the treatment of adult patients with relapsed or refractory (“R/R”) follicular lymphoma (“FL”) has been accepted for review and granted Priority Review by the China National Medical Products Administration (“NMPA”). Tazemetostat is a first-in-class methyltransferase inhibitor of EZH2 developed by Epizyme, Inc. (“Epizyme”), an Ipsen company. Tazemetostat is approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of certain patients with R/R FL and certain patients with advanced epithelioid sarcoma (“ES”) under the FDA accelerated approval program. It is also approved by the Japan Ministry of...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.